Brief: Alzamend Neuro Receives FDA “Study May Proceed” Notification For A Phase IIa Clinical Trial Of AL001, A Next‑Generation Lithium Therapeutic Drug Candidate, In Post-Traumatic Stress Disorder Patients

Alzamend Neuro

11/12/2023 13:08

Dec 11 (Reuters) - Alzamend Neuro Inc  ALZN.O :
    * ALZAMEND NEURO RECEIVES FDA “STUDY MAY PROCEED”
NOTIFICATION FOR
A PHASE IIA CLINICAL TRIAL OF AL001, A NEXT-GENERATION LITHIUM
THERAPEUTIC DRUG CANDIDATE, IN POST-TRAUMATIC STRESS DISORDER
PATIENTS
    * ALZAMEND NEURO INC - SAFETY ASPECTS OF AL001 DEVELOPMENT
MAY
QUALIFY FOR A 505(B)(2) NDA PATHWAY FOR FDA APPROVAL

Source text for Eikon:  ID:nBw5RQP6ca 
Further company coverage:  ALZN.O 

 ((Reuters.Briefs@thomsonreuters.com;))